Spots Global Cancer Trial Database for E3 Breast Cancer Taxotere Combination
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: E3 Breast Cancer Taxotere Combination
Official Title: A Phase II, Double-blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of ZD6474 in Combination With Docetaxel (Taxotere™) vs Docetaxel Alone as 2nd Line Treatment for Advanced Breast Cancer (ABC).
Study ID: NCT00494481
Conditions
Study Description
Brief Summary: To assess the efficacy of ZD6474 in combination with docetaxel in the treatment of ABC using the progression event count methodology
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Research Site, Budapest, , Hungary
Research Site, Pécs, , Hungary
Research SIte, Bloemfontein, , South Africa
Research Site, Cape Town, , South Africa
Research Site, Observatory, , South Africa
Research Site, Baracaldo, , Spain
Research SIte, Lérida, , Spain
Research Site, Zaragoza, , Spain
Research Site, Umeå, , Sweden
Research Site, Uppsala, , Sweden
Research Site, Västerås, , Sweden
Research Site, Taipei, , Taiwan
Contact Details
Name: Clinical Sciences & Operations
Affiliation: Sanofi
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
